The day's news flow in healthcare and biotech centred on cash and credibility: one company tore up its profit guidance as it absorbed the cost of taking control of its own US sales operation, while another drew a line under a placing that had been left incomplete for months. Between them, the two stories illustrate the capital pressures facing smaller life sciences names as they chase commercial scale.
Shield Therapeutics scraps profit forecast as US costs bite
Shield Therapeutics (AIM:STX) told investors on Tuesday that it now expects a single-digit US dollar million loss for the full year to 31 December, abandoning earlier guidance for operating profitability. The reversal lands as the company absorbs the costs of taking full US commercial control of its iron deficiency drug ACCRUFeR, and the market reaction was severe: shares collapsed 46.78% to 2.927p.
The guidance change came alongside an unaudited third-quarter trading update showing group net revenue up 2% quarter-on-quarter to $11.5 million, excluding a one-off milestone payment booked in the prior period. US ACCRUFeR net revenue rose 5% to $10.8 million, with average net revenue per prescription up 4% to $217, while ex-US revenue slipped to $0.7 million from $1.0 million. Cash stood at $6.8 million at quarter end. Dispensed prescriptions held broadly stable at around 49,000, with payer mix continuing to shift toward commercially insured patients as prior authorisation requirements introduced in the New York Medicaid programme took their toll on Medicaid volumes, commercial prescriptions rose 19% year-on-year for the nine months to 30 September against a 22% fall in Medicaid scripts. The company said the third quarter was the final period affected by that mandate. Shield took over full commercial responsibility for ACCRUFeR from its former US partner on 1 October, absorbing an 80-territory sales force in a move it says will materially improve gross margins and revenue retention over time.
"We are positioned to realise the full economic benefits of the US transaction, with an expanded proven commercial organisation, improving prescription mix, strong product positioning and customer focus which we believe will support long-term shareholder value creation," said Anders Lundstrom, Chief Executive.
The scale of the share price fall underscores how unforgiving investors are being toward near-term losses even when the underlying commercial transition has logic behind it. Shield's bet is that owning the full US sales infrastructure converts into better margins and prescription retention than the prior partnership model delivered, but that thesis now has to be proven against a lowered bar, with cash reserves of $6.8 million leaving little room for execution slippage as the newly internalised commercial organisation beds in.
Read the story →
Oxford BioDynamics closes out delayed placing shortfall
Oxford BioDynamics (AIM:OBD) confirmed on Tuesday that it has resolved an outstanding £250,000 shortfall from its August fundraise, meaning the precision diagnostics and 3D genomics company will now receive the full £9.15 million in gross proceeds originally targeted. The gap had persisted since Vulpes Investment Management, the original subscriber for that portion of the placing, failed to settle its allocation at admission.
The shortfall has now been closed by placing the 250 million shares in question at £0.001 each with three existing shareholders, with Vulpes' consent and the involvement of Singer Capital Markets and Merlin Partners, both parties to the original placing agreement. The broader raise, 9.15 billion new shares at £0.001 each, was approved by shareholders on 26 August and admitted to trading the following day, with Oxford BioDynamics disclosing on 1 October that all proceeds bar the Vulpes allocation had already been received, alongside an agreed extension of the payment deadline to 30 October.
With the reallocation complete, the placing agreement is now fully discharged, removing a lingering loose end from the company's balance sheet at a point where shares trade at 0.11p. The episode is a reminder of how fragile funding commitments can be even once shareholder approval and admission are secured, and the resolution, rather than a write-off or renegotiation, gives Oxford BioDynamics the full intended proceeds to fund its diagnostics pipeline without further dilution beyond what was already sanctioned.
Read the story →